Drug Type Small molecule drug |
Synonyms Encequidar, Encequidar mesylate (USAN), Encequidar mesylate monohydrate + [5] |
Target |
Action inhibitors |
Mechanism P-gp inhibitors(P-glycoprotein 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H42N6O11S |
InChIKeyDGJLRUWQERZYGC-UHFFFAOYSA-N |
CAS Registry2097125-58-9 |
Start Date23 Aug 2018 |
Sponsor / Collaborator |
Start Date20 Apr 2017 |
Sponsor / Collaborator |
Start Date01 Aug 2015 |
Sponsor / Collaborator [+2] |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 1 | China | 15 Aug 2019 | |
Breast Cancer | Phase 1 | China | 15 Aug 2019 | |
Solid tumor | Phase 1 | United States | 20 Apr 2017 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |